A Phase 3 interventional study of Epcoritamab and Prednisone in Follicular Lymphoma (FL), sponsored by Genmab. Active, not recruiting at 266 sites in 32 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-04.
Sponsored by Genmab · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies testing epcoritamab in Lymphoma, Follicular — 7 open to participants now, 12 under way, 2 of them phase 3. epcoritamab · Lymphoma, Follicular.
Among the 13 studies testing epcoritamab in Lymphoma, Follicular, this one has the largest enrollment, is one of 3 that started in 2024, is one of 2 in phase 3, reaches primary completion later than 11 of the 11 other live ones, and was the 7th registered.
1,891 studies on the registry are indexed under Lymphoma, Follicular; 289 are open to participants now.
Browse Lymphoma, Follicular studies →7 of the 13 studies testing epcoritamab in Lymphoma, Follicular are open now, in 4 countries. Recruiting first, the newest first:
Universität Münster · Sites in Germany
Ages 18+
Reid Merryman, MD · Sites in United States
Ages 18+
Beth Israel Deaconess Medical Center · Sites in United States
Ages 18+
Australasian Leukaemia and Lymphoma Group · Sites in Australia
Ages 18+
University of Birmingham · Sites in United Kingdom
Ages 18+
By country, each count listing its studies:
epcoritamab: first FDA approval 2023 (EPKINLY), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →
Of the 225 Lymphoma, Follicular studies recruiting now, 158 (70%) set no upper age limit and 39 (17%) stop at 75 or younger; 33 take children under 18; 24 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 11 · Phase 3 2
First in 2020; this study’s year is marked. 3 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,095 is above the median of 48 across 1,503 interventional studies indexed under Lymphoma, Follicular.
Median enrollment 78 across the 13 interventional studies. None of them has completed or been terminated yet.
This tab as a report to print or save as PDF → With an account.
4 of 13 have an industry lead sponsor. The 8 most frequent:
Genmab is the lead sponsor of 72 studies on the registry; 15 are open to participants now.
Of its 23 completed or terminated interventional studies of FDA-regulated products, 13 (57%) have results posted.
Genmab has 5 studies filed under Lymphoma, Follicular — fewer than ten, so there is no comparison to draw.
5 of the studies testing epcoritamab in Lymphoma, Follicular that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06287398Australasian Leukaemia and Lymphoma GroupEpcoritamab (Epcor)-Containing Combination Salvage Therapy Followed by ASCT & Epcor Consolidation in Patients With Relapsed LBCL | 2026-11 |
| NCT06510361Beth Israel Deaconess Medical CenterA Phase 2 Study of Epcoritamab in Patients With Follicular Lymphoma and Marginal Zone Lymphoma Not Accomplishing a Complete Response With Upfront Therapy | 2027-05-01 |
| NCT06112847City of Hope Medical CenterLenalidomide and Epcoritamab for the Treatment of Previously Untreated Follicular Lymphoma | 2027-08-10 |
| NCT04542824GenmabTrial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-NHL) | 2027-09 |
| NCT04663347GenmabSafety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL) | 2027-09-30 |
Add all 5 to your calendar (.ics) → With an account.
Among the 13 studies testing epcoritamab in Lymphoma, Follicular, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Follicular lymphoma (FL) is the second most common B-cell cancer and the most common type of cancer of lymphocytes. Unfortunately, this disease is incurable with conventional treatment and the disease recurs in almost all patients. This study will assess how safe and effective epcoritamab is in combination with lenalidomide and rituximab (R2) in treating adult participants with previously untreated FL. Adverse events and change in disease condition will be assessed.
Epcoritamab is an investigational drug being developed for the treatment of FL. Study doctors put the participants in 1 of 5 groups, called treatment arms. Each group receives a different treatment. Around 1095 adult participants with previously untreated FL will be enrolled in approximately 250 sites across the world.
Participants will receive R2 (intravenous [IV] infusion of rituximab (R) and oral capsules of lenalidomide) alone or in combination with subcutaneous injections of epcoritamab. Participants may also receive investigator's choice chemoimmunotherapy (CIT): IV infusion of obinutuzumab (G) and IV injections of cyclophosphamide, IV injections of doxorubicin, IV injections of vincristine, oral tablets of prednisone (CHOP) [G-CHOP]/ R-CHOP or G and IV infusion of bendamustine (Benda) [G-Benda]/R-Benda. The total treatment duration will be 120 weeks for all arms except A2, which is 24 weeks of treatment.
There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Has one or more target lesions:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive epcoritamab in combination with R2 (ER2), followed by epcoritamab during the 120 week treatment duration.
Drug: Epcoritamab · Drug: Rituximab · Drug: Lenalidomide
Participants will receive epcoritamab in combination with R2 (ER2), during the 24 week treatment duration.
Drug: Epcoritamab · Drug: Rituximab · Drug: Lenalidomide
Participants will receive CIT Option A (obinutuzumab (G) and cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) \[G-CHOP\]/ rituximab (R)-CHOP during the 120 week treatment duration.
Drug: Prednisone · Drug: Rituximab · Drug: Doxorubicin · Drug: Vincristine · Drug: Cyclophosphamide · Drug: Obinutuzumab
Participants will receive CIT Option B (G and bendamustine (Benda) \[G-Benda\]/R-Benda during the 120 week treatment duration.
Drug: Prednisone · Drug: Rituximab · Drug: Obinutuzumab · Drug: Bendamustine
Participants will receive lenalidomide and rituximab (R2) during the 120 week treatment duration.
Drug: Rituximab · Drug: Lenalidomide
Subcutaneous (SC) Injection
Also known as: ABBV-GMAB-3013, GEN3013, Epkinly
Oral Tablet
Intravenous (IV) Infusion
Oral Capsule
IV Injection
IV Injection
IV Injection
IV Infusion
IV Infusion
Arm A1 vs Arm B: Percentage of Participants who Achieve Complete Response rate at 30 months (CR30)
CR30 will be determined by positron emission tomography-computerized tomography (cat scan) \[PET-CT\] per Lugano 2014 criteria, as assessed by independent review committee (IRC).
Time frame: Up to 30 Months
Arm A1 vs Arm B: Number of Participants with Progression-free survival (PFS)
PFS is defined as the time from randomization until disease progression determined by Lugano 2014 criteria per IRC, or death, whichever occurs first.
Time frame: Up to 10 Years
Arm A1 vs Arm B: Overall Survival (OS)
OS is defined as the time from the date of randomization to the date of death of any cause.
Time frame: Up to 10 Years
Arm A1 vs Arm B: Rate of Minimal Residual Disease (MRD) Negativity Rate
MRD negativity rate, defined as the absence of tumor specific molecules in whole blood and/or bone marrow in participants with follicular lymphoma (FL) MRD at baseline.
Time frame: Up to 10 Years
Arm A1 vs Arm B: Change from Baseline in Physical Functioning (PF) According to European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Cancer (EORTC QLQ-C30)
The PF of EORTC QLQ-C30 is a 5-item questionnaire to assess the physical function of the participant, with a higher score indication worse functioning.
Time frame: 21 Weeks
Arm A1 vs Arm A2: Percentage of Participants who Achieve CR30
CR30 will be determined by PET-CT per Lugano 2014 criteria, as assessed by IRC.
Time frame: Up to 30 Months
Arm A1 vs Arm C: Percentage of Participants who Achieve CR30
CR30 will be determined by PET-CT per Lugano 2014 criteria, as assessed by IRC.
Time frame: Up to 30 Months
Arm A1 vs Arm A2: Number of Participants with PFS
PFS is defined as the time from randomization until disease progression determined by Lugano 2014 criteria per IRC, or death, whichever occurs first.
Time frame: Up to 10 Years
Arm A1 vs Arm C: Number of Participants with PFS
PFS is defined as the time from randomization until disease progression determined by Lugano 2014 criteria per IRC, or death, whichever occurs first.
Time frame: Up to 10 Years
Arm A1 vs Arm A2: Rate of MRD Negativity
MRD negativity, defined as the absence of tumor specific molecules in whole blood and/or bone marrow in participants with FL MRD at baseline.
Time frame: Up to 10 Years
Arm A1 vs Arm C: Rate of MRD Negativity
MRD negativity, defined as the absence of tumor specific molecules in whole blood and/or bone marrow in participants with FL MRD at baseline.
Time frame: Up to 10 Years
Arm A1 vs Arm A2: Change from Baseline in PF According to EORTC QLQ-C30
The PF of EORTC QLQ-C30 is a 5-item questionnaire to assess the physical function of the participant, with a higher score indication worse functioning.
Time frame: Up to 10 Years
Arm A1 vs Arm C: Change from Baseline in PF According to EORTC QLQ-C30
The PF of EORTC QLQ-C30 is a 5-item questionnaire to assess the physical function of the participant, with a higher score indication worse functioning.
Time frame: Up to 10 Years
Arm A1 vs Arm A2: OS
OS is defined as the time from the date of randomization to the date of death of any cause.
Time frame: Up to 10 Years
Arm A1 vs Arm C: OS
OS is defined as the time from the date of randomization to the date of death of any cause.
Time frame: Up to 10 Years
Arm A1 vs Arm A2: Percentage of Participants who Achieve CR30
CR30 will be determined by PET-CT per Lugano 2014 criteria, as assessed by investigator.
Time frame: Up to 30 Months
Arm A1 vs Arm B: Percentage of Participants who Achieve CR30
CR30 will be determined by PET-CT per Lugano 2014 criteria, as assessed by investigator.
Time frame: Up to 30 Months
Arm A1 vs Arm C: Percentage of Participants who Achieve CR30
CR30 will be determined by PET-CT per Lugano 2014 criteria, as assessed by investigator.
Time frame: Up to 30 Months
Arm A1 vs Arm A2: Number of Participants with PFS
PFS is defined as the time from randomization until disease progression determined by Lugano 2014 criteria per investigator, or death, whichever occurs first.
Time frame: Up to 10 Years
Arm A1 vs Arm B: Number of Participants with PFS
PFS is defined as the time from randomization until disease progression determined by Lugano 2014 criteria per investigator, or death, whichever occurs first.
Time frame: Up to 10 Years
Arm A1 vs Arm C: Number of Participants with PFS
PFS is defined as the time from randomization until disease progression determined by Lugano 2014 criteria per investigator, or death, whichever occurs first.
Time frame: Up to 10 Years
Arm A1 vs Arm A2: Percentage of Participants with Change in CR Rate per IRC
CR will be determined by PET-CT per Lugano 2014 criteria, as assessed by IRC.
Time frame: Up to 10 Years
Arm A1 vs Arm A2: Percentage of Participants with Change in CR Rate per Investigator
CR will be determined by PET-CT per Lugano 2014 criteria, as assessed by investigator.
Time frame: Up to 10 Years
Arm A1 vs Arm B: Percentage of Participants with Change in CR Rate per IRC
CR will be determined by PET-CT per Lugano 2014 criteria, as assessed by IRC.
Time frame: Up to 10 Years
Arm A1 vs Arm B: Percentage of Participants with Change in CR Rate per Investigator
CR will be determined by PET-CT per Lugano 2014 criteria, as assessed by investigator.
Time frame: Up to 10 Years
Arm A1 vs Arm C: Percentage of Participants with Change in CR Rate per IRC
CR will be determined by PET-CT per Lugano 2014 criteria, as assessed by IRC.
Time frame: Up to 10 Years
Arm A1 vs Arm C: Percentage of Participants with Change in CR Rate per Investigator
CR will be determined by PET-CT per Lugano 2014 criteria, as assessed by investigator.
Time frame: Up to 10 Years
Arm A1 vs Arm A2: Number of Participants with Best Overall Response (BOR) per per Investigator
BOR is defined as the percentage of participants who achieve CR or partial response (PR) determined by Lugano 2014 criteria as assessed by investigator, or death from any cause.
Time frame: Up to 10 Years
Arm A1 vs Arm A2: Number of Participants with BOR per IRC
BOR is defined as the percentage of participants who achieve CR or PR determined by Lugano 2014 criteria as assessed by IRC, or death from any cause.
Time frame: Up to 10 Years
Arm A1 vs Arm B: Number of Participants with BOR per Investigator
BOR is defined as the percentage of participants who achieve CR or PR determined by Lugano 2014 criteria as assessed by investigator, or death from any cause.
Time frame: Up to 10 Years
Arm A1 vs Arm B: Number of Participants with BOR per IRC
BOR is defined as the percentage of participants who achieve CR or PR determined by Lugano 2014 criteria as assessed by IRC, or death from any cause.
Time frame: Up to 10 Years
Arm A1 vs Arm C: Number of Participants with BOR per Investigator
BOR is defined as the percentage of participants who achieve CR or PR determined by Lugano 2014 criteria as assessed by investigator, or death from any cause.
Time frame: Up to 10 Years
Arm A1 vs Arm C: Number of Participants with BOR per IRC
BOR is defined as the percentage of participants who achieve CR or PR determined by Lugano 2014 criteria as assessed by IRC, or death from any cause.
Time frame: Up to 10 Years
Arm A1 vs Arm A2: Number of Participants with Event-free Survival (EFS) per IRC
EFS is defined as the time from randomization until adverse event determined by Lugano 2014 criteria per IRC, or death, whichever occurs first.
Time frame: Up to 10 Years
Arm A1 vs Arm A2: Number of Participants with EFS per Investigator
EFS is defined as the time from randomization until adverse event determined by Lugano 2014 criteria per investigator, or death, whichever occurs first.
Time frame: Up to 10 Years
Arm A1 vs Arm B: Number of Participants with EFS per IRC
EFS is defined as the time from randomization until adverse event determined by Lugano 2014 criteria per IRC, or death, whichever occurs first.
Time frame: Up to 10 Years
Arm A1 vs Arm B: Number of Participants with EFS per Investigator
EFS is defined as the time from randomization until adverse event determined by Lugano 2014 criteria per investigator, or death, whichever occurs first.
Time frame: Up to 10 Years
Arm A1 vs Arm C: Number of Participants with EFS per IRC
EFS is defined as the time from randomization until adverse event determined by Lugano 2014 criteria per IRC, or death, whichever occurs first.
Time frame: Up to 10 Years
Arm A1 vs Arm C: Number of Participants with EFS per Investigator
EFS is defined as the time from randomization until adverse event determined by Lugano 2014 criteria per investigator, or death, whichever occurs first.
Time frame: Up to 10 Years
Arm A1 vs Arm A2: Duration of Response (DOR) per IRC
DOR is defined as the time from PR or CR to disease progression per Lugano 2014 criteria, as assessed by IRC.
Time frame: Up to 10 Years
Arm A1 vs Arm A2: DOR per Investigator
DOR is defined as the time from PR or CR to disease progression per Lugano 2014 criteria, as assessed by investigator.
Time frame: Up to 10 Years
Arm A1 vs Arm B: DOR per IRC
DOR is defined as the time from PR or CR to disease progression per Lugano 2014 criteria, as assessed by IRC.
Time frame: Up to 10 Years
Arm A1 vs Arm B: DOR per Investigator
DOR is defined as the time from PR or CR to disease progression per Lugano 2014 criteria, as assessed by investigator.
Time frame: Up to 10 Years
Arm A1 vs Arm C: DOR per IRC
DOR is defined as the time from PR or CR to disease progression per Lugano 2014 criteria, as assessed by IRC.
Time frame: Up to 10 Years
Arm A1 vs Arm C: DOR per Investigator
DOR is defined as the time from PR or CR to disease progression per Lugano 2014 criteria, as assessed by investigator.
Time frame: Up to 10 Years
Arm A1 vs Arm A2: Duration of Complete Response (DOCR) per IRC
DOCR is defined as the time from CR to disease progression per Lugano 2014 criteria, as assessed by IRC.
Time frame: Up to 10 Years
Arm A1 vs Arm A2: DOCR per Investigator
DOCR is defined as the time from CR to disease progression per Lugano 2014 criteria, as assessed by investigator.
Time frame: Up to 10 Years
Arm A1 vs Arm B: DOCR per IRC
DOCR is defined as the time from CR to disease progression per Lugano 2014 criteria, as assessed by IRC.
Time frame: Up to 10 Years
Arm A1 vs Arm B: DOCR per Investigator
DOCR is defined as the time from CR to disease progression per Lugano 2014 criteria, as assessed by investigator.
Time frame: Up to 10 Years
Arm A1 vs Arm C: DOCR per IRC
DOCR is defined as the time from CR to disease progression per Lugano 2014 criteria, as assessed by IRC.
Time frame: Up to 10 Years
Arm A1 vs Arm C: DOCR per Investigator
DOCR is defined as the time from CR to disease progression per Lugano 2014 criteria, as assessed by investigator.
Time frame: Up to 10 Years
Arm A1 vs Arm A2: Time to Next Anti-lymphoma Therapy (TTNT) per Investigator
TTNT is defined as the time from randomization to first documented administration of subsequent anti-lymphoma therapy.
Time frame: Up to 10 Years
Arm A1 vs Arm A2: TTNT per IRC
TTNT is defined as the time from randomization to first documented administration of subsequent anti-lymphoma therapy.
Time frame: Up to 10 Years
Arm A1 vs Arm A2: TTNT per Investigator
TTNT is defined as the time from randomization to first documented administration of subsequent anti-lymphoma therapy.
Time frame: Up to 10 Years
Arm A1 vs Arm B: TTNT per IRC
TTNT is defined as the time from randomization to first documented administration of subsequent anti-lymphoma therapy.
Time frame: Up to 10 Years
Arm A1 vs Arm B: TTNT per Investigator
TTNT is defined as the time from randomization to first documented administration of subsequent anti-lymphoma therapy.
Time frame: Up to 10 Years
Arm A1 vs Arm C: TTNT per IRC
TTNT is defined as the time from randomization to first documented administration of subsequent anti-lymphoma therapy.
Time frame: Up to 10 Years
Arm A1 vs Arm C: TTNT per Investigator
TTNT is defined as the time from randomization to first documented administration of subsequent anti-lymphoma therapy.
Time frame: Up to 10 Years
Arm A1 vs Arm A2: Time to Progression per IRC
Time to progression defined as the time from randomization to disease progression per Lugano 2014 criteria, as assessed by IRC.
Time frame: Up to 10 Years
Arm A1 vs Arm A2: Time to Progression per Investigator
Time to progression defined as the time from randomization to disease progression per Lugano 2014 criteria, as assessed by investigator.
Time frame: Up to 10 Years
Arm A1 vs Arm B: Time to Progression per IRC
Time to progression defined as the time from randomization to disease progression per Lugano 2014 criteria, as assessed by IRC.
Time frame: Up to 10 Years
Arm A1 vs Arm B: Time to Progression per Investigator
Time to progression defined as the time from randomization to disease progression per Lugano 2014 criteria, as assessed by investigator.
Time frame: Up to 10 Years
Arm A1 vs Arm C: Time to Progression per IRC
Time to progression defined as the time from randomization to disease progression per Lugano 2014 criteria, as assessed by IRC.
Time frame: Up to 10 Years
Arm A1 vs Arm C: Time to Progression per Investigator
Time to progression defined as the time from randomization to disease progression per Lugano 2014 criteria, as assessed by investigator.
Time frame: Up to 10 Years
Arm A1 vs Arm A2: Number of Participants with Progression-free Survival After Subsequent Anti-Lymphoma Therapy (PFS2)
PFS2 is defined as the time after subsequent anti-lymphoma therapy to the earliest occurrence of disease progression determined by Lugano 2014 criteria as assessed by investigator, or death from any cause.
Time frame: Up to 10 Years
Arm A1 vs Arm B: Number of Participants with PFS2
PFS2 is defined as the time after subsequent anti-lymphoma therapy to the earliest occurrence of disease progression determined by Lugano 2014 criteria as assessed by investigator, or death from any cause.
Time frame: Up to 10 Years
Arm A1 vs Arm C: Number of Participants with PFS2
PFS2 is defined as the time after subsequent anti-lymphoma therapy to the earliest occurrence of disease progression determined by Lugano 2014 criteria as assessed by investigator, or death from any cause.
Time frame: Up to 10 Years
Arm A1 vs Arm A2: Change in Tolerability as Measured by Patient Reported Outcomes-Common Terminology Criteria for Adverse Events (PRO-CTCAE)
The PRO-CTCAE is a patient-reported outcome measurement system developed to assess symptomatic toxicity in participants in cancer clinical trials. PRO-CTCAE items evaluate common symptoms from study treatment on their frequency, severity, interference, amount, presence/absence.
Time frame: Up to 10 Years
Arm A1 vs Arm B: Change in Tolerability as Measured by PRO-CTCAE
The PRO-CTCAE is a patient-reported outcome measurement system developed to assess symptomatic toxicity in participants in cancer clinical trials. PRO-CTCAE items evaluate common symptoms from study treatment on their frequency, severity, interference, amount, presence/absence.
Time frame: Up to 10 Years
Arm A1 vs Arm C: Change in Tolerability as Measured by PRO-CTCAE
The PRO-CTCAE is a patient-reported outcome measurement system developed to assess symptomatic toxicity in participants in cancer clinical trials. PRO-CTCAE items evaluate common symptoms from study treatment on their frequency, severity, interference, amount, presence/absence.
Time frame: Up to 10 Years
Arm A1 vs Arm A2: Change in Tolerability as Measured by The Functional Assessment of Cancer Therapy - General (FACT-G) Item GP5
The functional assessment of cancer therapy singly item - GP5 (FACT-GP5) is a single question asking if participant is bothered by side effects of treatment.
Time frame: Up to 10 Years
Arm A1 vs Arm B: Change in Tolerability as Measured by FACT-G Item GP5
The FACT-GP5 is a single question asking if participant is bothered by side effects of treatment.
Time frame: Up to 10 Years
Arm A1 vs Arm C: Change in Tolerability as Measured by FACT-GG Item GP5
The FACT-GP5 is a single question asking if participant is bothered by side effects of treatment.
Time frame: Up to 10 Years
Arm A1 vs Arm A2: Change in Symptoms as Measured by The Functional Assessment of Cancer Therapy - Lymphoma (FACT-Lym)
The objective of the FACT-Lym patient reported outcome (PRO) is to assess health-related quality of life issues for adult lymphoma patients. It utilizes a 5-point Likert-type scale.
Time frame: Up to 10 Years
Arm A1 vs Arm B: Change in Symptoms as Measured by FACT-Lym
The objective of the FACT-Lym patient reported outcome (PRO) is to assess health-related quality of life issues for adult lymphoma patients. It utilizes a 5-point Likert-type scale.
Time frame: Up to 10 Years
Arm A1 vs Arm C: Change in Symptoms as Measured by FACT-Lym
The objective of the FACT-Lym patient reported outcome (PRO) is to assess health-related quality of life issues for adult lymphoma patients. It utilizes a 5-point Likert-type scale.
Time frame: Up to 10 Years
Arm A1 vs Arm A2: Change in Quality of Life (QoL) as Measured by FACT-Lym
The objective of the FACT-Lym PRO is to assess health-related quality of life issues for adult lymphoma patients. It utilizes a 5-point Likert-type scale.
Time frame: Up to 10 Years
Arm A1 vs Arm B: Change in QoL as Measured by FACT-Lym
The objective of the FACT-Lym PRO is to assess health-related quality of life issues for adult lymphoma patients. It utilizes a 5-point Likert-type scale.
Time frame: Up to 10 Years
Arm A1 vs Arm C: Change in QoL as Measured by FACT-Lym
The objective of the FACT-Lym PRO is to assess health-related quality of life issues for adult lymphoma patients. It utilizes a 5-point Likert-type scale.
Time frame: Up to 10 Years
Arm A1 vs Arm A2: Time-to-first PRO deterioration (TTD) in well-being using the lymphoma subscale (LymS) of FACT-Lym
The objective of the FACT-Lym PRO is to assess health-related quality of life issues for adult lymphoma patients. It utilizes a 5-point Likert-type scale.
Time frame: Up to 10 Years
Arm A1 vs Arm B: TTD in well-being using LymS of FACT-Lym
The objective of the FACT-Lym PRO is to assess health-related quality of life issues for adult lymphoma patients. It utilizes a 5-point Likert-type scale.
Time frame: Up to 10 Years
Arm A1 vs Arm C: TTD in well-being using LymS of FACT-Lym
The objective of the FACT-Lym PRO is to assess health-related quality of life issues for adult lymphoma patients. It utilizes a 5-point Likert-type scale.
Time frame: Up to 10 Years
Arm A1 vs Arm A2: Change in QoL as Measured by 5-Level European Quality of Life (EuroQol)-5-dimension [EQ-5D-5L]
The EQ-5D-5L is a standardized, non-disease specific instrument used to measure health-related quality of life. The EQ-5D-5L assesses general health on 5 dimensions (mobility, self-care, usual activities, pain/discomfort and anxiety/depression). Each dimension has 5 levels (no problems, slight problems, moderate problems, severe problems, and extreme problems). The scores for the 5 dimensions are used to compute a single utility index score ranging from 0 to 1 representing the general health status of the individual, with higher scores indicating better health state.
Time frame: Up to 10 Years
Arm A1 vs Arm B: Change in QoL as Measured by EQ-5D-5L
The EQ-5D-5L is a standardized, non-disease specific instrument used to measure health-related quality of life. The EQ-5D-5L assesses general health on 5 dimensions (mobility, self-care, usual activities, pain/discomfort and anxiety/depression). Each dimension has 5 levels (no problems, slight problems, moderate problems, severe problems, and extreme problems). The scores for the 5 dimensions are used to compute a single utility index score ranging from 0 to 1 representing the general health status of the individual, with higher scores indicating better health state.
Time frame: Up to 10 Years
Arm A1 vs Arm C: Change in QoL as Measured by EQ-5D-5L
The EQ-5D-5L is a standardized, non-disease specific instrument used to measure health-related quality of life. The EQ-5D-5L assesses general health on 5 dimensions (mobility, self-care, usual activities, pain/discomfort and anxiety/depression). Each dimension has 5 levels (no problems, slight problems, moderate problems, severe problems, and extreme problems). The scores for the 5 dimensions are used to compute a single utility index score ranging from 0 to 1 representing the general health status of the individual, with higher scores indicating better health state.
Time frame: Up to 10 Years
Arm A1 vs Arm A2: TTD in PF using the QLQ-C30 Physical Functioning Scale
The PF of EORTC QLQ-C30 is a 5-item questionnaire to assess the physical function of the participant, with a higher score indication worse functioning.
Time frame: Up to 10 Years
Arm A1 vs Arm B: TTD in PF using the QLQ-C30 Physical Functioning Scale
The PF of EORTC QLQ-C30 is a 5-item questionnaire to assess the physical function of the participant, with a higher score indication worse functioning.
Time frame: Up to 10 Years
Arm A1 vs Arm C: TTD in PF using the QLQ-C30 Physical Functioning Scale
The PF of EORTC QLQ-C30 is a 5-item questionnaire to assess the physical function of the participant, with a higher score indication worse functioning.
Time frame: Up to 10 Years
Arm A1 vs Arm A2: Change from baseline in the remaining items and domains of the EORTC QLQ-C30
The EORTC QLQ-C30: A 30 items questionnaire to assess the quality of life of cancer patients on physical, emotional, cognitive, and social functions and symptoms. with a higher score indication worse quality of life.
Time frame: Up to 10 Years
Arm A1 vs Arm B: Change from baseline in the remaining items and domains of the EORTC QLQ-C30
The EORTC QLQ-C30: A 30 items questionnaire to assess the quality of life of cancer patients on physical, emotional, cognitive, and social functions and symptoms. with a higher score indication worse quality of life.
Time frame: Up to 10 Years
Arm A1 vs Arm C: Change from baseline in the remaining items and domains of the EORTC QLQ-C30
The EORTC QLQ-C30: A 30 items questionnaire to assess the quality of life of cancer patients on physical, emotional, cognitive, and social functions and symptoms. with a higher score indication worse quality of life.
Time frame: Up to 10 Years
Arm A1 vs Arm A2: Change in Patient Global Impression of Change (PGIC) for General Lymphoma Symptoms
The self-report measure PGIC reflects a participant's belief about the efficacy of treatment. The PGIC is a 7-point scale depicting a participant's rating of overall improvement since start of treatment. Participants rate their change as very much improved, much improved, minimally improved, no change, minimally worse, much worse, or very much worse.
Time frame: Up to 10 Years
Arm A1 vs Arm C: Change in PGIC for General Lymphoma Symptoms
The self-report measure PGIC reflects a participant's belief about the efficacy of treatment. The PGIC is a 7-point scale depicting a participant's rating of overall improvement since start of treatment. Participants rate their change as very much improved, much improved, minimally improved, no change, minimally worse, much worse, or very much worse.
Time frame: Up to 10 Years
Arm A1 vs Arm A2: Change in Patient Global Impression of Severity (PGIS) for General Lymphoma Symptoms
The self-report measure PGIS reflects a participant's belief about their lymphoma symptoms over the past 7 days. The PGIS is a 5-point scale depicting a participant's rating of overall severity.
Time frame: Up to 10 Years
Arm A1 vs Arm B: Change in PGIS for General Lymphoma Symptoms
The self-report measure PGIS reflects a participant's belief about their lymphoma symptoms over the past 7 days. The PGIS is a 5-point scale depicting a participant's rating of overall severity.
Time frame: Up to 10 Years
Arm A1 vs Arm C: Change in PGIS for General Lymphoma Symptoms
The self-report measure PGIS reflects a participant's belief about their lymphoma symptoms over the past 7 days. The PGIS is a 5-point scale depicting a participant's rating of overall severity.
Time frame: Up to 10 Years
Showing the first 100 of 266 sites across 32 countries. Choose a country and city above to see the rest.
Plan to share: Yes — AbbVie is committed to responsible clinical trial data sharing. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols, analyses plans, clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.
Supporting information: Study protocol, Statistical analysis plan
Time frame: For details on when studies are available for sharing visit https://vivli.org/ourmember/abbvie/
Access criteria: To learn more about the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/
Data sharing details ↗ · vivli.org
No publications or documents are linked to this record.
Started Feb 2024 (actual). Primary completion is estimated for Nov 2037, 165 months after the start.
Of 45 industry-sponsored phase 3 interventional studies under Lymphoma, Follicular, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 86. This study's planned 165 months is above that.
Counting every sponsor, half of 80 studies reached it within 63 months; a quarter within 36 and three quarters within 106.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Epcoritamab · Lenalidomide